



## Revance Announces Closing of Public Offering of Common Stock

January 22, 2019

### Gross Proceeds of Offering Total 115.0 Million

NEWARK, Calif.--(BUSINESS WIRE)--Jan. 22, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced the closing of an underwritten public offering of 6,764,705 shares of its common stock at a price to the public of \$17.00 per share, including the exercise in full by the underwriters of their option to purchase 882,352 additional shares of common stock. The gross proceeds to the Company from the offering, before deducting the underwriters' discounts and other estimated offering expense payable by the Company, were approximately \$115.0 million.

Goldman Sachs & Co. LLC, Cowen and Piper Jaffray acted as book-running managers and Guggenheim Securities acted as lead manager.

The securities described above were offered by Revance pursuant to an automatic shelf registration statement previously filed with the Securities and Exchange Commission on December 5, 2017. The offering was made only by means of a prospectus supplement. When available, copies of the prospectus supplement and accompanying prospectus relating to the proposed public offering may be obtained by contacting Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing [prospectus-ny@ny.email.gs.com](mailto:prospectus-ny@ny.email.gs.com); Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by emailing [PostSaleManualRequests@broadridge.com](mailto:PostSaleManualRequests@broadridge.com); or Piper Jaffray & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924, or by email at [prospectus@pic.com](mailto:prospectus@pic.com).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

### About Revance Therapeutics, Inc.

Revance is a clinical-stage biotechnology company focused on the development, manufacturing, and commercialization of novel neuromodulators for multiple aesthetic and therapeutic indications. Revance is leveraging its proprietary portfolio of botulinum toxin type A compounds, formulated with its patented and proprietary peptide excipient technology, to address unmet needs in large and growing neuromodulator markets.

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190122005823/en/>

Source: Revance Therapeutics, Inc.

### INVESTORS

Revance Therapeutics, Inc.:  
Jeanie Herbert, 714-325-3584  
[jherbert@revance.com](mailto:jherbert@revance.com)

or

Burns McClellan, Inc.:  
John Grimaldi, 212-213-0006  
[jgrimaldi@burnsmc.com](mailto:jgrimaldi@burnsmc.com)

or

### MEDIA

General Media:  
TOGORUN:  
Mariann Caprino, 917-242-1087  
[m.caprino@togorun.com](mailto:m.caprino@togorun.com)

or

Trade Media:  
Nadine Tosk, 504-453-8344  
[nadinepr@gmail.com](mailto:nadinepr@gmail.com)